Although a putative role for transforming growth factor- (TGFB) signalling in the pathogenesis of human endometrial cancer has long been proposed, the precise function of TGFB signalling in the development and progression of endometrial cancer remains elusive. Depletion of phosphatase and tensin homologue (PTEN) in the mouse uterus causes endometrial cancer. To identify the potential role of TGFB signalling in endometrial cancer, we simultaneously deleted TGFB receptor 1 (Tgfbr1) and Pten in the mouse uterus by using Cre-recombinase driven by the progesterone receptor (termed Pten 
Introduction
Approximately 61 380 new cases of and 10 920 deaths from uterine corpus cancers, the majority of which are endometrial cancers, are projected to occur in 2017 in the USA [1] . There are two major types of endometrial cancer. Type I cancers are mostly endometrioid adenocarcinomas that are associated with excess oestrogen. Type II cancers are mainly composed of serous carcinomas that are oestrogen-independent, with overall poorer prognoses [2] . The mechanisms of endometrial cancer development are not well defined, and effective prophylactic and therapeutic approaches are needed. Therefore, understanding the molecular mechanisms underlying the pathogenesis of endometrial cancer is an essential step towards developing novel targeted therapies.
Phosphatase and tensin homologue (PTEN), a tumour suppressor gene, is mutated in a variety of human 90 Y Gao et al circulation, extravasation, and colonization, is the major cause of morbidity and mortality in cancer patients [6] . To establish distant metastasis, cancer cells originating from the primary site acquire an enhanced ability to migrate and invade. Myometrial invasion is an important factor for the diagnosis and staging of endometrial cancer. The depth of myometrial invasion has been used as a criterion for staging endometrial cancers by the International Federation of Gynecology and Obstetrics (FIGO), whereby FIGO stages IA and IB refer to endometrial cancers with no or <50% myometrial invasion and those with ≥50% myometrial invasion, respectively [7] . Moreover, a higher risk of extrauterine metastases has been found in endometrial cancer patients with >50% myoinvasion than in those with <50% myoinvasion [8] . Endometrial cancer can metastasize to other organs, with the common sites being the lymph nodes, vagina, peritoneum, and lung [9, 10] . It has been increasingly recognized that the cancer microenvironment is critical for metastasis by promoting adhesion, survival, extracellular matrix proteolysis, cell migration/invasion, immune escape, and angiogenesis [11] . Chemokines and their receptors are important regulators of many cancer cell properties, such as proliferation, invasion, apoptosis, and metastasis [12] . Moreover, tumour-associated macrophages (TAMs), a major population of infiltrating leukocytes and well-known immunosuppressive cells, have been shown to promote cancer growth, invasion, and metastasis [13] . It is of note that metastasis has not been reported in the mouse model of endometrial cancer with uterine Pten depletion [5, 14] , indicating a need to create additional models with which to study the metastatic process and associated mechanisms of this gynaecological malignancy.
Transforming growth factor-β (TGFB) signalling is known to be tumour-suppressive. Many essential elements of this pathway, including the ligands, receptors, and SMAD transducers, are mutated and/or altered in human diseases, including cancers [15] . In vitro studies have suggested that TGFB signalling regulates endometrial cancer cell proliferation, survival, invasion, and metastasis [16] [17] [18] . However, the contribution of TGFB signalling to the pathogenesis of endometrial cancer at the organism level remains to be determined. Therefore, the aim of this study was to explore the role of TGFB signalling in endometrial cancer development and progression by creating a mouse model that harbours concurrent deletion of TGFB receptor 1 (Tgfbr1) and Pten in the uterus.
Materials and methods

Animals
Mice were on a mixed C57BL/6/129 genetic background, and the use of mice for this study was approved by the Institutional Animal Care and Use Committee at Texas A&M University. The Pgr-Cre and Tgfbr1 flox mice were generated previously [19, 20] . The Pgr-Cre mice were obtained from J. Lydon and F. DeMayo, and the Tgfbr1 flox mice were contributed by S. Karlsson and imported from the Matzuk Laboratory at Baylor College of Medicine. The Pten flox mice were purchased from The Jackson Laboratory (stock no. 006440; The Jackson Laboratory, Bar Harbor, ME, USA) [21] . The genotypes of mice and DNA recombination were analysed by genomic polymerase chain reaction (PCR) (supplementary material, Table S1 ) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Histology, immunohistochemistry, and immunofluorescence
Tissue samples were fixed in 10% neutral buffered formalin (Sigma, St Louis, MO, USA), embedded in paraffin wax, and cut into 5-μm-thick sections for haematoxylin and eosin (H&E) staining, immunohistochemistry, or immunofluorescence, as described previously [30] . Antibody details are shown in supplementary material, Table S2 .
Western blotting
Western blotting was conducted as described previously [30] , with the indicated primary antibodies (supplementary material, Table S2 ). Quantification of western blots was performed with NIH ImageJ (version 1.50i). Data are presented as percentages; the levels of target proteins in the Pten d/d group were set to 100%. Table S1 and iTaq Universal SYBR Green Supermix (Bio-Rad) [29] .
Enzyme-linked immunosorbent assay (ELISA)
Serum
Statistical analysis
Statistical analysis was performed with GraphPad Prism (version 7.01). Data are mean ± standard error of the mean (SEM). Comparisons between two means were performed with two-tailed t-tests (unpaired). Comparisons of means among multiple groups were performed with one-way ANOVA followed by Holm-Sidak pairwise comparisons. Survival curves were analysed with the log-rank/Mantel-Cox test. Significantly skewed data were log-transformed prior to ANOVA. Statistical significance was defined as *P < 0.05, **P < 0.01, and ***P < 0.001.
Results
Generation of mice harbouring simultaneous deletion of Pten and Tgfbr1
Pten Pgr-Cre conditional knockout (termed Pten d/d ) mice develop endometrial cancer [5] . To determine the function of TGFB signalling in endometrial cancer, we simultaneously ablated Pten and Tgfbr1 in the mouse uterus by using Pgr-Cre. To examine the expression of Figure S7 ). In contrast, grossly visible metastases were evident in the lungs of Figure 4A ; supplementary material, Figure S8A and Table S3 ). Unlike the lungs of Pten d/d mice, which showed highly organized alveolar structures ( Figure 4B ), the lungs of
mice showed multiple metastatic sites, consisting of pathological lesions with variable differentiation status ( Figure 4C-G) . In addition, the metastasis was frequently accompanied by haemorrhage and loss of morphologically normal alveoli (supplementary material, Figure S8A ; Figure 4C -G). Using immunohistochemistry, we further verified that the metastatic nodules were positive for KRT8 ( Figure 4I ; supplementary material, Figure S8C ) and ER ( Figure 4K ), but were negative for PGR ( Figure 4M ). Figure S8F ). The metastatic nodules also expressed mucin 1 (MUC1) (Figure 4O ), a protein that is frequently overexpressed in metastatic cancers [31] . Representative immunostaining of the lungs from Pten f/f ;Tgfbr1 f/f controls is shown in Figure 4H , J, L, N. To confirm that pulmonary metastasis was specific to Loss of TGFBR1 increases the production of proinflammatory chemokines associated with cancer metastasis of metastasis resulting from ablation of TGFBR1, we compared uterine mRNA expression of chemokines, including Cxcl1, Cxcl5, Cxcl12, Ccl2, and Ccl9, and a chemokine receptor, Cxcr2, that are involved in metastasis [33] [34] [35] [36] 
Discussion
Mutation or inactivation of TGFB signalling components has been associated with the development of a broad array of cancers [40] . Although a putative role for TGFB signalling in the pathogenesis of human endometrial cancer has long been proposed [41] , the precise function of TGFB signalling in endometrial cancer development has remained elusive. PTEN mutations have been identified in a variety of cancers. Loss of PTEN, a negative regulator of the PI3K-AKT pathway, is involved in the oncogenesis of endometrial carcinoma [42] . Conditional deletion of Pten in the mouse uterus by the use of Pgr-Cre leads to the development of endometrial malignancy, which phenocopies many pathological characteristics of human endometrial cancer [5] . As a result, the Pten d/d mouse model has been used to study resulting from either local or distant metastases remains devastating. Endometrial cancer has been reported to have the highest frequency of pulmonary metastases (20-25%) among gynaecological cancers [9, 10] . Therefore, development of an endometrial cancer model with organ metastases mimicking human endometrial cancer is critical for understanding metastatic initiation and progression.
Little is known about the potential interplay between TGFB signalling and PTEN during endometrial carcinogenesis, although their interactions have been documented in other tumours [45, 46] . Inactivation of TGFB signalling and loss of growth inhibition are associated with the development of human endometrial cancer [47, 48] . It has been shown that mutations of TGFB signalling components, including TGFB receptors and SMADs, and alteration of TGFB signalling activity reflected by changes in gene expression and/or phosphorylation of key signalling proteins play a role in the patho-aetiology of human endometrial cancer [47, 49, 50] . TGFBR1 has a 5.6% mutation and alteration rate in human endometrial cancer [49, 51] . As reported, cancerous human endometrium expresses lower levels of TGFBR1 protein [47, 52] . TGFBR2 is mutated/altered in 6.5% of endometrial tumours [49, 51] . Studies from The Cancer Genome Atlas Research Network have also suggested alterations of several SMADs in human endometrial cancer [49, 51] . Of particular importance was the availability of the two endometrial cancer models (i.e. and progression of endometrioid adenocarcinoma, the most frequent type of endometrial cancer in women. However, it needs to be pointed out that, owing to the expression of Pgr-Cre in uterine stromal cells and the myometrium, a potential impact of TGFBR1 and/or PTEN loss in these cellular compartments on the tumour phenotype cannot be excluded, and this may represent a limitation of the current study. Future investigations are needed to address this question by using Cre lines targeting distinct cellular compartments of the uterus.
Metastasis is a complex process in which cancer cells can disseminate via the bloodstream and/or lymphatics to establish secondary tumours at the metastatic sites. Because of the involvement of chemokines in the process of metastasis, therapeutic strategies targeting the action of chemokines may block/attenuate metastasis. A functional link between TGFB signalling and chemokines during cancer metastasis has emerged [33, 53, 54] . In one study, conditional ablation of TGFBR2 in mammary fibroblasts increased the secretion of CCL2, which promoted mammary cancer progression at least partially through a TAM-dependent mechanism [33] . Enhanced production of CCL9 resulting from loss of TGFB signalling promotes immature myeloid cell infiltration and the development of invasive intestinal tumours [55] . Loss of TGFB signalling in mouse mammary epithelial cells promotes metastasis by recruiting myeloid-derived suppressor cells into tumour tissues via the CXCL5-CXCR2 and CXCL12-CXCR4 axes [34] . The increased transcript levels of Cxcl5 and [34]. This finding, together with the role of CXCL5 in cell invasion and metastasis in several types of cancers, including bladder cancer [56] , mammary cancer [34] , and liver cancer [57] , suggests that activation of the CXCL5-CXCR2 axis resulting from loss of TGFBR1 may contribute to the pulmonary metastasis of endometrial cancer induced by conditional abrogation of PTEN in the uterus. Importantly, we showed that serum levels of CXCL5 and CCL2 were elevated in Pten
mice as compared with Pten d/d mice. As CXCL5 expression is increased in human endometrial cancer tissues as compared with normal endometrium [58] , it would be useful to further explore the potential of CXCL5 and CCL2 as biomarkers for endometrial cancer patients.
Studies using genetically modified mice have revealed the emerging role of TAMs in the development of invasive endometrial cancer [59, 60] . However, the involvement of uterine TGFB signalling in TAM recruitment and polarization and the contribution of TAMs to the development of endometrial cancer remain to be elucidated. At advanced stages of tumour development, CD163 + cells were readily detectable and the expression of CD163 was increased in the uteri of Pten [61] . The fact that the deletion of Tgfbr1 in the PTEN-inactivated uterus accelerates endometrial cancer progression also highlights the complex role of TGFB signalling in vivo, where compensatory pathways may function to promote cancer invasion/metastasis in the absence of TGFBR1.
In summary, conditional deletion of Pten and Tgfbr1 leads to a disease that recapitulates invasive and lethal endometrial cancer. This new mouse model is potentially valuable for preclinical testing of targeted therapies to treat endometrial cancer with metastasis. Table S1 . Primers for conventional PCR and RT-qPCR Table S2 . Primary antibodies for immunostaining and western blotting 
SUPPLEMENTARY MATERIAL ONLINE
